Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00671645
Other study ID # ABCSG R04/TAKO 08
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date July 2008
Est. completion date February 27, 2009

Study information

Verified date October 2020
Source Austrian Breast & Colorectal Cancer Study Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

- feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma - collection of response rate (T- and M-downstaging, pathological complete remission)


Description:

Combined RadioChemotherapy: Therapy start: within 28 days after bioptical diagnosis Radiotherapy: 5 x 5 days 1.8 Gy radiotherapy; cummulative dose 45 Gy Chemotherapy: Capecitabin 825mg/m² bid, on each radiation day during the first 4 weeks RCTx Molecular Targeted Therapy: Bevacizumab 5 mg/kg body weight; day 1, 15, 29 Operation due to TME adherence to a break of min. 42 to max. 56 days after the last application of bevacizumab


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date February 27, 2009
Est. primary completion date February 27, 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - age: 18 - 80 - bioptical confirmed adenocarcinoma of the rectum in T3NxM0 status. The tumor has to be basically surgically complete resectable (->R0). - no former chemotherapy, radiotherapy of pelvis or abdomen and/or tumor resection of rectum carcinoma - WHO performance status 0-2 - adequate bone marrow reserve (granulocytes >= 3.000/µl, absolute neutrophil >= 0 1,5 x 10 9/l thrombocytes: >= 100.000/µl, haemoglobin >= 10g/dl) - adequate hepatic function (Bilirubin: <= 1.5 x ULN, GOT und GPT <= 2.5 x ULN) - adequate renal function (creatinin: <= 1.25 mg/dl, creatinin-clearance: > 50 ml/min (Cockcroft and Gault formula)), proteinuria: dipstick < 2+. In case of dipstick > 2+ protein has to be measured in 24h urine and does not exceed more than 1g/24h) - ability of intake of pills - women of childbearing potential: exclusion of pregnancy (negative urin or serum pregnancy test) - willingness of women of childbearing potential and accordingly of potent men to use approved contraceptives (e.g. birth-control pill, loop, condom) during and at least 3 month after conclusion of the study - life expectancy of at least 3 month - INR and aPTT < 1.5 ULN - signed Informed Consent before recruitment Exclusion Criteria: - failure of one inclusion criteria - former radiotherapy of pelvis or abdomen - former chemotherapy - any other kind of malign tumor in the last 5 years - any other kind of tumour in the last 5 years with exception of basal cell carcinoma of skin and cervix carcinoma in situ - general contraindication or known hypersensitivity against Bevacizumab and/or Capecitabine - non malign disease, if there is a contraindication with radiotherapy, or chemotherapy with Bevacizumab and Capecitabine, or a resection of rectum: uncontrolled hypertension (systolic > 150 mmHG and/or diastolic >100 mmHG) or clinical significant (e.g. active) cardiovascular disease: CVA (cardiovascular accident)/ cerebral apoplexy (< 6 months before recruitment), myocardial infarct (< 6 months before recruitment), instable angina pectoris, CHF with NYHA status II or higher, or treated serious arrhythmia, hepatic disease, significant neurologic or psychiatric disorders - florid, serious infections at the time of recruitment - peripheral neuropathy (NCI CTC >= Grade 1) - legally limited contractual capability or evidence of neurological or psychiatric disease, if it will constrict the patients compliance in the opinion of the investigator - evidence of lacking cooperation of the patient - major intervention within 28 days before recruitment, open wounds - serious injuries, unhealed wounds or fractures - patients with spinal compressions or metastases in central nervous system - evidence of bleeding diathesis or coagulation dysfunction - actual intake of anticoagulant or thrombolytic agents, Aspirin > 325 mg/d or within 10 days before study start) - actual or recent (within 10 days before recruitment) therapeutic therapy with fully-dosed anticoagulants. A prophylactic treatment is permitted. - previous thromboembolic or hemorrhagic events within the last 6 months before recruitment - previous abdominal fistulas, GI perforation or intra-abdominal abscess within the last 6 months - treatment with other study medication within 28 days before recruitment - patients with malabsorption syndrome or difficulties swallowing - pregnant or breast feeding women

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
capecitabine, bevacizumab
Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29

Locations

Country Name City State
Austria State Hospital Feldkirch, Radiotherapy Feldkirch Vorarlberg
Austria Medical University Graz, Oncology Graz Styria
Austria Medical University Innsbruck, Internal Medicine Innsbruck Tyrol
Austria State Hospital Leoben, Surgery Leoben Styria
Austria Hospital BHS Linz, Radiooncology Linz Upper Austria
Austria State Hospital Salzburg-Paracelsius Medical University - Oncology Salzburg
Austria Hospital BHB St. Veit/Glan, Surgery St. Veit/Glan Carinthia
Austria Hospital BHB Vienna, Surgery Vienna
Austria Medical University Vienna, Radiotherapy Vienna
Austria Klinikum Wels-Grieskirchen, Coop. Group Wels Upper Austria

Sponsors (2)

Lead Sponsor Collaborator
Austrian Breast & Colorectal Cancer Study Group Hoffmann-La Roche

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma descriptive evaluation
Secondary collection of response rate (T- and M-downstaging, pathological complete remission) descriptive evaluation
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A

External Links